10 Best Small-Cap Biotech Stocks to Buy According to Analysts

7. Edgewise Therapeutics, Inc. (NASDAQ:EWTX

Number of Hedge Fund Holders: 38

Upside Potential: 72.45%

Edgewise Therapeutics, Inc. (NASDAQ:EWTX) is one of the best small-cap biotech stocks to buy according to analysts.

Edgewise Therapeutics, Inc. (NASDAQ:EWTX) reported its Q3 2025 results on November 6, 2025. The quarter marked continued advancement of its muscular dystrophy and cardiac programs. Meanwhile, its critical GRAND CANYON cohort for sevasemten in Becker muscular dystrophy remains well-positioned for readout in Q4 2026. At the same time, the MESA open-label extension trial noted continued enrollment of nearly all eligible participants. The quarter also saw the Phase 2 CIRRUS-HCM trial of EDG-7500 in hypertrophic cardiomyopathy progressing well, with a program update expected in Q4 2025. Phase 1 dosing of EDG-15400 for heart failure also kicked off.

Due to the clinical activity in EDC-15400, EDC-7500, and the sevasemten program, R&D expenses surged by $3.9 million to $37.5 million, compared to the same quarter a year earlier. With G&A expenses up $0.3 million sequentially, Edgewise Therapeutics, Inc. (NASDAQ:EWTX) recorded a net loss of $40.7 million, or $0.39 per share.

Yet Edgewise Therapeutics, Inc. (NASDAQ:EWTX) closed the quarter with $563.3 million in cash balances, sufficient to provide a runway to support ongoing clinical development and potential future commercial launches.

Edgewise Therapeutics, Inc. (NASDAQ:EWTX), a biopharmaceutical company, develops new therapies for muscular dystrophies and serious cardiac conditions.